Overview
RDY market data
Price History
RDY price chart · 1M
- O
- 12.12
- H
- 12.23
- L
- 12.07
- C
- 12.19
- Vol
- 252,588.00
- Source
- US equities market feed
- Observed
- Aug 21, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $12.12
- Previous Close
- $12.12
- Day High
- $12.23
- Day Low
- $12.07
- 52 Week High
- $15.58
- 52 Week Low
- $11.30
- 7 Day Return
- -0.65%
- 30 Day Return
- +7.50%
- 90 Day Return
- -10.89%
- 1 Year Return
- -13.97%
- Daily Notional Volume
- $3.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 31.22 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $50.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.18 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.7% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 9.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1,101.00 – $1,414.90 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1T · P/B 2.76 · P/S 3.03.
Company News
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement TerminationBenzinga · Aug 7, 2026, 3:36 PM
Dr. Reddy's Expands Hospital Portfolio With First-To-Market Sugammadex Injection Launch, Targeting Neuromuscular Blockade Reversal In Surgery PatientsBenzinga · Aug 4, 2026, 6:50 AM
Dr. Reddy’s Laboratories Announces U.S. FDA Completes Inspection at Srikakulam Unit, Issues Form 483Benzinga · Jul 29, 2026, 4:29 PM
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff ThreatBenzinga · Jul 22, 2026, 6:12 PM
Dr. Reddy's Laboratories shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, President Trump announced a 100% import tariffs on imported generic drugs after a two-year grace period.Benzinga · Jul 22, 2026, 2:33 PM
Dr. Reddy's Executive During Earnings Conference Call Says Company Has Launched Generic Semaglutide Tablets In India; Not Practical To Move To U.S. Immediately Amid Tariff Environment; Working To Resume Semaglutide Supplies At Earliest; Hoping To Get Semaglutide To Market By NovemberBenzinga · Jul 22, 2026, 12:33 PM
Dr Reddy's Laboratories Q1 EPS $0.06 Misses $0.17 Estimate, Sales $853.000M Miss $925.530M EstimateBenzinga · Jul 22, 2026, 11:30 AM
Earnings Scheduled For July 22, 2026Benzinga · Jul 22, 2026, 11:11 AM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial PneumoniaBenzinga · Jun 16, 2026, 12:10 PM